Immunome Inc (IMNM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immunome Inc (IMNM) has a cash flow conversion efficiency ratio of -0.076x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-47.95 Million) by net assets ($634.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Immunome Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Immunome Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Immunome Inc for a breakdown of total debt and financial obligations.
Immunome Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunome Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Terna Energy Societe Anonyme Commercial Technical Company
AT:TENERGY
|
0.071x |
|
Ardagh Metal Packaging SA
NYSE:AMBP
|
-0.542x |
|
China Aluminum International Engineering Corp Ltd
SHG:601068
|
0.053x |
|
Dentsply Sirona Inc
NASDAQ:XRAY
|
0.053x |
|
Ningbo Boway Alloy Material Co Ltd
SHG:601137
|
-0.062x |
|
OliX PharmaceuticalsInc
KQ:226950
|
0.023x |
|
Washington Federal Inc
NASDAQ:WAFD
|
0.020x |
|
Easyhome New Retail Group Co Ltd
SHE:000785
|
0.036x |
Annual Cash Flow Conversion Efficiency for Immunome Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Immunome Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Immunome Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $634.34 Million | $-190.92 Million | -0.301x | +50.79% |
| 2024-12-31 | $181.16 Million | $-110.79 Million | -0.612x | -868.76% |
| 2023-12-31 | $119.88 Million | $-7.57 Million | -0.063x | +96.34% |
| 2022-12-31 | $16.65 Million | $-28.69 Million | -1.723x | -355.47% |
| 2021-12-31 | $48.19 Million | $-18.23 Million | -0.378x | -28.88% |
| 2020-12-31 | $41.34 Million | $-12.13 Million | -0.293x | -208.92% |
| 2019-12-31 | $-35.63 Million | $-9.60 Million | 0.269x | -8.30% |
| 2018-12-31 | $-25.20 Million | $-7.41 Million | 0.294x | -- |
About Immunome Inc
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine… Read more